Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire CEO Angus Russell On The Value Proposition For Drugs

Executive Summary

Since 2008, Shire PLC 's market cap has nearly doubled ($8.3 billion to $16 billion) and its employee count has grown from 1,600 to roughly 4,300. Analysts say the U.K. company is on track to deliver its revenue guidance of 15% compound annual growth rate (CAGR) through 2015 – far above the expected anemic performance of most pharmaceutical companies.

You may also be interested in...

On A Revenue Roll, Shire Takes Specialist Tactics To “Primary Care” Markets

Shire targets specialist segments of vast primary care populations, with focus on areas of unmet need.

As Pharma Falters, Shire Specialist Model Hits Sweet Spot

With product sales growth that most big pharmas can only dream of, Shire's specialist model is working.

Rare Disease Research: Where Compassion Meets Commerce

The advent of a new set of potential acquirers has heightened venture capital's interest in rare diseases, resulting in the creation of a new cohort of drug developers that are using cutting edge technologies to treat and in some cases cure grave illnesses. In this issue, we profile Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts